Related Experiment Video
Updated: Jun 26, 2025
Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies
Published on: June 20, 2015
The Peptidoglycan Recognition Protein 1 confers immune evasive properties on pancreatic cancer stem cells
Juan Carlos López-Gil1,2,3, Susana García-Silva4, Laura Ruiz-Cañas1,2,5
1Cancer Stem Cells and Fibroinflammatory Microenvironment Group, Cancer Department, Instituto de Investigaciones Biomédicas (IIBM) Sols-Morreale CSIC-UAM, Madrid, Spain.
Objective:
Pancreatic ductal adenocarcinoma (PDAC) has limited therapeutic options, particularly with immune checkpoint inhibitors. Highly chemoresistant 'stem-like' cells, known as cancer stem cells (CSCs), are implicated in PDAC aggressiveness. Thus, comprehending how this subset of cells evades the immune system is crucial for advancing novel therapies.
Design:
We used the KPC mouse model (LSL-KrasG12D/+; LSL-Trp53R172H/+; Pdx-1-Cre) and primary tumour cell lines to investigate putative CSC populations. Transcriptomic analyses were conducted to pinpoint new genes involved in immune evasion. Overexpressing and knockout cell lines were established with lentiviral vectors. Subsequent in vitro coculture assays, in vivo mouse and zebrafish tumorigenesis studies, and in silico database approaches were performed.
Results:
Using the KPC mouse model, we functionally confirmed a population of cells marked by EpCAM, Sca-1 and CD133 as authentic CSCs and investigated their transcriptional profile. Immune evasion signatures/genes, notably the gene peptidoglycan recognition protein 1 (PGLYRP1), were significantly overexpressed in these CSCs. Modulating PGLYRP1 impacted CSC immune evasion, affecting their resistance to macrophage-mediated and T-cell-mediated killing and their tumourigenesis in immunocompetent mice. Mechanistically, tumour necrosis factor alpha (TNFα)-regulated PGLYRP1 expression interferes with the immune tumour microenvironment (TME) landscape, promoting myeloid cell-derived immunosuppression and activated T-cell death. Importantly, these findings were not only replicated in human models, but clinically, secreted PGLYRP1 levels were significantly elevated in patients with PDAC.
Conclusions:
This study establishes PGLYRP1 as a novel CSC-associated marker crucial for immune evasion, particularly against macrophage phagocytosis and T-cell killing, presenting it as a promising target for PDAC immunotherapy.
Insights
Peptidoglycan recognition protein 1 (PGLYRP1) is overexpressed in pancreatic cancer stem cells (CSCs), enabling immune evasion. Targeting PGLYRP1 offers a promising new strategy for pancreatic ductal adenocarcinoma (PDAC) immunotherapy.
Area of Science:
- Cancer Biology
- Immunology
- Molecular Oncology
Background:
- Pancreatic ductal adenocarcinoma (PDAC) exhibits limited treatment options, especially with immune checkpoint inhibitors.
- Highly chemoresistant cancer stem cells (CSCs) contribute to PDAC's aggressive nature and immune evasion.
- Understanding CSC immune evasion mechanisms is vital for developing effective PDAC therapies.
Purpose of the Study:
- To identify novel genes involved in immune evasion utilized by pancreatic cancer stem cells (CSCs).
- To investigate the role of identified genes in CSC-mediated immune suppression and tumor progression.
- To evaluate the therapeutic potential of targeting these immune evasion mechanisms in PDAC.
Main Methods:
- Utilized the KPC mouse model and primary tumor cell lines to isolate and characterize CSC populations.
- Conducted transcriptomic analyses to identify immune evasion-associated genes.
- Employed lentiviral vectors for gene overexpression and knockout studies, followed by in vitro and in vivo assays, including coculture, tumorigenesis studies in mice and zebrafish, and in silico analyses.
Main Results:
- Functionally confirmed EpCAM, Sca-1, and CD133-marked cells as authentic CSCs in the KPC model.
- Identified peptidoglycan recognition protein 1 (PGLYRP1) as significantly overexpressed in CSCs, correlating with immune evasion signatures.
- Demonstrated that modulating PGLYRP1 affects CSC resistance to macrophage and T-cell mediated killing, impacting tumor growth. Tumor necrosis factor alpha (TNFα) regulates PGLYRP1, promoting immunosuppression and T-cell death within the tumor microenvironment (TME). Elevated PGLYRP1 levels were observed in human PDAC patients.
Conclusions:
- Establishes PGLYRP1 as a novel CSC-associated marker critical for immune evasion in PDAC.
- Highlights PGLYRP1's role in evading macrophage phagocytosis and T-cell mediated killing.
- Presents PGLYRP1 as a promising therapeutic target for enhancing PDAC immunotherapy.
Related Concept Videos
02:40Cancer Stem Cells and Tumor Maintenance
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
01:58Cell Specific Gene Expression